Spots Global Cancer Trial Database for Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Official Title: A Phase II/III Clinical Trial With Ex Vivo Expanded Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Study ID: NCT03592706

Conditions

HepatoCellular Carcinoma

Liver Cancer

Interventions

IKC (Immune Killer Cells)

TACE (Transcatheter Arterial Chemoembolization)

Study Description

Brief Summary: The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients in： 1. Reduction of tumor size 2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.

Detailed Description: This is a phase II/III clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce the patented product IKC (Immune Killer Cells). The IKC will then infused back into the patient to treat the cancer. Each patient will receive a total of twelve infusions. 60 patients are anticipated to be recruited. This is a double-arm study, the experimental group will receive IKC treatment along with TACE treatment. The control group will receive only TACE treatment. 30 patients will be randomized into each arm.